GSK RoCCPORT Chronic Cough

This study is a multinational, multi-center, observational, prospective, cohort study of patients with refractory chronic cough/unexplained chronic cough (RCC/UCC) and patients without RCC/UCC using primary data collection.

Study phase: N/A

Study phase (if other): Observational

Basic eligibility criteria:
Please contact the study coordinator for additional eligibility information.

1. Age 21 years at study entry

2. Current or new patient in an outpatient respiratory/pulmonology, ENT, or allergy/immunology clinic being evaluated or treated for RCC/UCC

3. Willing and able to provide written informed consent to participate in the study in a manner approved by the IRB/IEC and local regulations

4. Willing to wear the cough monitor during the 4-week study period

5. Have cough lasting greater than 8 weeks prior to study entry Comparison Cohort participants must meet all the following criteria to be eligible for participation in the study: 1. Age ? 21 years at study entry

6. Current or new patient in an outpatient respiratory/pulmonology, ENT, or allergy/immunology clinic not being evaluated or treated for a respiratory disorder

7. Willing and able to provide written informed consent to participate in the study in a manner approved by the IRB/IEC and local regulations

8. Willing to wear the cough monitor during the 4-week study period
 

Primary disease category: Asthma & Lung

Secondary disease categories: Allergy & Immunology

Sponsor: GSK

Protocol number: 222179 RoCCPORT

Projected enrollment dates: June 2025 to December 2026

Official study title: A Prospective Cohort Study of Patients with Refractory or Unexplained Chronic Cough measuring Cough Variability and Burden on Patients’ Lives